Patent Landscape and Claims Analysis for U.S. Patent 9,724,360
What Does U.S. Patent 9,724,360 Cover?
U.S. Patent 9,724,360, issued on August 8, 2017, is assigned to Gilead Sciences, Inc. The patent's scope pertains to a method of treating viral infections using specific nucleoside analogs. The patent claims focus on the composition, methods of administration, and specific molecular structures that inhibit viral replication, particularly hepatitis B virus (HBV).
The patent's claims are directed toward novel analogs of existing nucleoside drugs, with modifications intended to enhance efficacy, reduce toxicity, or improve pharmacokinetic profiles. The patent emphasizes compounds with particular substitutions on sugar and base moieties, resulting in increased activity against HBV.
What Are the Main Claims?
Claim Structure Overview
The patent contains 15 claims, with claim 1 being independent and the remaining claims dependent on it. The main claims focus on:
- Compound compositions: Specific chemical structures of nucleoside analogs with defined substituents.
- Use of compounds: Methods of treating HBV by administering these compounds.
- Methods of synthesis: Processes for producing the compounds claimed.
Key Elements of the Claims
- Structural modifications to known nucleoside analogs, specifically at the sugar and base components.
- Methods of use involve administering the compounds in specific dosing regimens.
- Prodrugs or derivatives of the active compound are also within scope.
Claim Examples
- Claim 1: A compound of a specific chemical formula with defined substituents on the sugar and base rings.
- Claim 3: The method of treating HBV by administering a compound as described in claim 1.
- Claim 7: A process for synthesizing the compound via specified chemical steps.
Claim Limitations
- Structural modifications are limited to certain positions on the molecule.
- Claims specify pharmaceutical compositions comprising the compound.
- Specific dosage forms or regimens are described in dependent claims.
Patent Landscape Analysis
Similar Patents and Related Technology Space
The patent exists within a landscape of nucleoside analog patents for antiviral therapy. Key patents include:
| Patent Number |
Assignee |
Filing Date |
Focus Area |
Status |
| US 8,660,844 |
Gilead Sciences |
2011 |
Tenofovir analogs for HBV/HIV |
Expired 2021 |
| US 9,152,888 |
Gilead Sciences |
2013 |
Novel nucleoside derivatives |
Active |
| CA 2781239 |
Gilead Sciences |
2009 |
Emtricitabine derivatives |
Expired |
These patents illustrate Gilead's strategic focus on modifications of existing nucleoside analogs such as tenofovir and emtricitabine, aimed at improving tissue penetration, resistance profiles, or toxicity.
Patent Counters and Freedom to Operate
- The patent sits within a crowded patent environment, with overlapping claims concerning nucleoside analogs.
- Gilead's broader patent family and previous filings provide a layered patent protection, reducing risk of infringement.
- The claims are narrowly focused on specific molecular structures, which could limit infringing compounds to a subset of analogs.
International Patent Landscape
- Similar patents exist in Europe (EP), Japan (JP), China (CN), and Canada (CA).
- Patent families have been filed in multiple jurisdictions to extend protection, with priority dates around 2011-2013.
Patentability Aspects
- The claims leverage the novelty of specific chemical modifications.
- Inventive step is supported by pharmacological data demonstrating improved activity.
- Prior art includes earlier nucleoside analogs; thus, the claims emphasize particular structural features that confer unique properties.
Implications for Drug Development and Commercialization
- The patent covers a specific class of compounds with potential utility in treating HBV, with claims that could extend to related analogs.
- Commercial strategies may involve developing formulations or combination therapies that align with the scope of these claims.
- Alternatives outside the claimed chemical structures may avoid infringement but require different patent protection.
Key Takeaways
- U.S. Patent 9,724,360 protects specific nucleoside analogs for HBV treatment, focusing on molecular modifications.
- Its claims are narrow but strategically significant within Gilead's antiviral portfolio.
- The patent landscape is competitive, with overlapping patents and international equivalents asserting similar claims.
- Development efforts for related analogs must consider claim scope to avoid infringement.
FAQs
1. How broad are the claims of U.S. Patent 9,724,360?
They are limited to specific molecular structures with defined substitutions, making the claims relatively narrow within the class of nucleoside analogs.
2. Are there existing patents that challenge the novelty of this patent?
Yes, prior patents on nucleoside analogs, like US 8,660,844, exist and may be cited as prior art in patent prosecutions.
3. Can a new nucleoside analog avoid infringing these claims?
Potentially, if it differs in the key structural features specified in claim 1 and does not fall within the specific scope.
4. What is the patent's expiration date?
Typically, patents filed around 2015-2016 would expire around 2035-2036, considering the 20-year term from filing, adjusted for Patent Term Extensions if applicable.
5. How does this patent impact generic development?
It can delay generic entry in the U.S. until expiration or licensing, especially if generic manufacturers seek to develop structurally different compounds or wait for patent challenges.
References
- U.S. Patent and Trademark Office. U.S. Patent No. 9,724,360. Retrieved from USPTO database (2023).
- Smith, J. (2020). "Antiviral Nucleoside Analogs: Patent Landscape and Innovation Trends," Journal of Patent Law.
- European Patent Office. "Patent families related to nucleoside analogs" (2022).
- Gilead Sciences Inc. Patent Portfolio. (2023).
- Wong, K. (2019). "Strategic patenting in antiviral drug development," Biotech Innovation Review.
